Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Transcript: President Obama Town Hall meeting in New Hampshire

President Barack Obama continued his press for public support of health reform initiatives at what the White House called a "Health Insurance Reform Town Hall" meeting at Portsmouth High School in Portsmouth, New Hampshire.

12 Aug 2009

Most people overestimate the life-saving benefits of breast and prostate cancer screening

A public survey conducted in Europe found that the vast majority of people overestimate the life-saving benefits of breast and prostate cancer screening, according to a new study published online August 12 in the Journal of the National Cancer Institute.

12 Aug 2009

$Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer$

Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer

Twice-yearly treatment with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer.

11 Aug 2009

Importance of PSA testing in high-risk men, stressed by National Comprehensive Cancer Network

The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Guidelines for Prostate Cancer Early Detection incorporating the results of the recent ERSPC trial that assessed the benefit of PSA screening. The NCCN Guidelines contend that PSA screening does save lives when performed intelligently in men at high-risk of developing the disease.

11 Aug 2009

Dendreon signs lease for new manufacturing facility in Union City, Ga

Dendreon Corporation (Nasdaq: DNDN) today announced it has signed a lease agreement with Majestic Realty Co. to build a 160,000 square-foot manufacturing facility in Union City, Ga., where it expects to manufacture PROVENGE(R) (sipuleucel-T) for patients with advanced prostate cancer. The state of Georgia will be hosting a ribbon-cutting ceremony on September 30.

10 Aug 2009

Decode Genetics announces Q2 2009 financials

deCODE genetics (Nasdaq: DCGN) today announced its consolidated financial results for the quarter ended June 30, 2009. A conference call to discuss these results and recent developments in the company's business will be webcast live tomorrow, Tuesday, August 11, at 8:00am Eastern Daylight Time/12 noon GMT/1pm British Summer Time (details below).

10 Aug 2009

Gtx, Inc. reports Q2 2009 results

GTx, Inc. (Nasdaq: GTXI) today reported financial results for the second quarter of 2009. The net loss for the second quarter and six months ended June 30, 2009 was $11.3 million and $22.6 million, respectively, compared with a net loss of $13.2 million and $26.0 million for the same periods in 2008. At June 30, 2009 GTx had cash, cash equivalents and short-term investments of $68.9 million.

10 Aug 2009

Oncogenex Pharmaceuticals issued key patent

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer drug candidate, OGX-011, to treat certain cancers.

10 Aug 2009

Bob Monkhouse on a Twitter campaign for prostate cancer awareness

Bob Monkhouse, who was brought back to life by The Communications Agency to raise awareness (and a few bob) for the Prostate Cancer Research Foundation, is now twittering from beyond the grave.

10 Aug 2009

NIH stimulus funding supports Emory - grants to advance research, create jobs, support students

At least 50 research projects so far, supported by more than $10 million in stimulus grants from the National Institutes of Health, are expected to lead to new discoveries at Emory University that will improve medical treatment, create new jobs, and provide additional educational opportunities for students. Emory has received half of all the NIH ARRA grants awarded to Georgia academic institutions thus far.

9 Aug 2009

Bellicum Pharmaceuticals starts phase I/II trial of novel advanced prostate cancer vaccine

Bellicum Pharmaceuticals, Inc. today announced dosing of the first patient in a Phase I/II clinical trial of BP-GMAX-CD1, a novel pharmacologically regulated dendritic cell vaccine for the treatment of prostate cancer. The disease-specific trial is being conducted under a Bellicum Investigational New Drug application allowed by the FDA in 2008. The company anticipates reporting initial results of the study in 2010.

6 Aug 2009

Senate Dems prepare contingency plans as finance negotiators grapple for a deal

"Senate Democrats may decide to pass a U.S. health-care overhaul without Republican support if some opposition lawmakers don't agree to a plan by mid-September," Senator Charles Schumer[ D-N.Y.] said" according to Bloomberg. Schumer said Sen. Max Baucus, D-Mont., set a self-imposed deadline of Sept. 15 to lead a negotiating team, composed of three Republicans and three Democrats within his Finance Committee, to a bipartisan compromise.

4 Aug 2009

Heavy drinkers have much higher risk of developing cancer

Heavy drinkers of beer and spirits face a much higher risk of developing cancer than the population at large, says a group of Montreal epidemiologists and cancer researchers.

4 Aug 2009

Will emphasis on prevention bring health costs down?

If there is one thing that both parties can agree on in the health overhaul debate, it’s the need to build a health system that promotes prevention rather than just manages disease.

4 Aug 2009

Seed implants suitable prostate cancer treatment for men of all ages

Men diagnosed with prostate cancer have a number of treatments to choose from, but it's a daunting task to figure out the right mix of therapies for an individual patient.

3 Aug 2009

Heavy consumption of beer and spirits to 6 different cancers

Heavy drinkers of beer and spirits face a much higher risk of developing cancer than the population at large, says a group of Montreal epidemiologists and cancer researchers. Their findings show that people in the highest consumption category increased their risk of developing oesophageal cancer sevenfold, colon cancer by 80% and even lung cancer by 50%.

3 Aug 2009

New nano-gene therapy technique could fight late-stage tumors

Tiny particles carrying a killer gene can effectively suppress ovarian tumor growth in mice, according to a team of researchers from MIT and the Lankenau Institute.

31 Jul 2009

Epigenetic signature changes in low oxygen levels may contribute to prostate cancer development

UCD Conway researchers have characterised epigenetic signature changes in prostate cells under conditions of low oxygen levels that may lead to tumour development.

30 Jul 2009

Study finds few patients die from prostate cancer within 15 years of radical prostatectomy

Investigators at Memorial Sloan-Kettering Cancer Center (MSKCC), along with collaborating teams at the Cleveland Clinic and the University of Michigan, have completed the first large- scale, multi-institutional study of prostate cancer death after standard treatment to remove the prostate since PSA screening has become widely used as a method to screen for the disease.

28 Jul 2009

Anxiety and distress during active surveillance for early prostate cancer

Men with early stages of prostate cancer who delay radical treatment in favor of an approach of "expectant management" do not have high levels of anxiety and distress. That is the conclusion of a new study published in the September 1, 2009 issue of Cancer, a peer-reviewed journal of the American Cancer Society.

27 Jul 2009